CWF19L1 Antibody

Code CSB-PA727965LA01HU
Size US$166
Order now
Image
  • Western blot
    All lanes: CWF19L1 antibody at 4µg/ml + Raji whole cell lysate
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 61, 28, 46 kDa
    Observed band size: 61 kDa

  • Immunohistochemistry of paraffin-embedded human colon tissue using CSB-PA727965LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human pancreatic tissue using CSB-PA727965LA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) CWF19L1 Polyclonal antibody
Uniprot No.
Target Names
CWF19L1
Alternative Names
CWF19L1CWF19-like protein 1 antibody; C19L1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human CWF19-like protein 1 protein (101-330AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The CWF19L1 Antibody (Product code: CSB-PA727965LA01HU) is Non-conjugated. For CWF19L1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA727965LB01HU CWF19L1 Antibody, HRP conjugated ELISA
FITC CSB-PA727965LC01HU CWF19L1 Antibody, FITC conjugated
Biotin CSB-PA727965LD01HU CWF19L1 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Gene References into Functions
  1. Our report corroborates that loss-of-function mutations in CWF19Ll lead to early onset cerebellar ataxia and (progressive) cerebellar atrophy. PMID: 27016154
  2. Two pathogenic variants in CWF19L1 were identified in a patient with autosomal recessive cerebellar ataxia. c.37G>C variant was inherited from the father and the c.946A>T variant from the mother. PMID: 26197978
  3. Results of protein-protein interaction between human Dbr1 and factors found in the Intron Large complex identify Xab2 and a novel protein CWF19L1 as specific interactors of DBR1. PMID: 25671812
  4. CWF19L1 mutations may be a novel cause of recessive ataxia with developmental delay PMID: 25361784
  5. Our findings suggest ERLIN1-CHUK-CWF19L1 variants are associated with early stage of fatty liver accumulation to hepatic inflammation. PMID: 23477746

Show More

Hide All

Involvement in disease
Spinocerebellar ataxia, autosomal recessive, 17 (SCAR17)
Protein Families
CWF19 family
Tissue Specificity
Expressed in many brain regions, including cerebellum, thalamus and occipital, parietal and temporal lobes (at protein level). Also expressed in the spinal cord (at protein level).
Database Links

HGNC: 25613

OMIM: 616120

KEGG: hsa:55280

STRING: 9606.ENSP00000326411

UniGene: Hs.215502

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*